Please assess the completion status of the following clinical trial:

Trial Title: Study to IDEntify Patients With Advanced/Metastatic Non Small Cell Lung Cancer (NSCLC) and ALK and ROS1 Translocation and to Establish Their Therapeutic Management (IDEALK&ROS)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: OTHER
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~For ALK Incidence substudy~* Patients with Advanced or metastatic non-small cell lung cancer~* Patients who will be screened for anaplastic lymphoma kinase (ALK) rearrangement~* Age \> 18 years For ALK treatment substudy (retrospective and prospective)~* Age \> 18 years~* Confirmed anaplastic lymphoma kinase (ALK)-positive tumour~* Patients treated with crizotinib under routine clinical practice~* Patients with a minimum data registered at the medical history~* For the patients that will be recruited prospectively: Patients must have a signed informed consent document.~For the ROS1 treatment sub-study (retrospective only):~* Age \> 18 years~* Confirmation of NSCLC with ROS1-positive translocation~* Have been eligible to receive treatment with crizotinib according to routine clinical practice since the market launch of the ROS1 indication in Spain on 8 February 2017 until the opening of the site.~* Patients should have a predetermined minimum amount of data recorded in their medical records.~Exclusion Criteria:~* Any patient who does not meet any of the inclusion criteria defined in the previous section, depending on the sub-study for which they are included.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Routine clinical practice group (NSCLC ALK+, ROS1) (Type: None): Patients diagnosed and treated following routine clinical practice, for their NSCLC ALK+ or ROS1

Based on this trial design, predict the completion outcome and termination type (if applicable).